Denteric is a biotechnology startup specializing in oral health, particularly in the development of vaccines to treat and prevent severe periodontal disease. This debilitating gum disease affects one in ten people globally, causing damage to the soft tissue and bone that support the teeth. The company operates in the healthcare and biotechnology market, targeting both individual patients and dental health professionals.

The business model of Denteric revolves around extensive research and development (R&D) to create effective vaccines. By leveraging the expertise of its leadership team, which includes notable figures like Laureate Professor Eric Reynolds AO and Anne Laure, the company aims to bring innovative solutions to market. Professor Reynolds has a distinguished background in dental health, while Anne Laure brings a wealth of experience in immunology and business development.

Denteric makes money primarily through the development and eventual commercialization of its vaccines. This involves securing funding for R&D, conducting clinical trials, and obtaining regulatory approvals. Once the vaccines are approved, the company plans to generate revenue through sales to healthcare providers, dental clinics, and potentially through partnerships with larger pharmaceutical companies.

In summary, Denteric is a cutting-edge biotech firm focused on combating severe periodontal disease through innovative vaccine development, aiming to improve global oral health.

Keywords: Biotechnology, Oral Health, Vaccines, Periodontal Disease, Research, Development, Healthcare, Innovation, Dental, Immunology.